Alzheimer's Treatment Breakthroughs 2026
2026 Alzheimer's breakthroughs: at-home Leqembi, pill-based therapies in trials, brain stimulation devices. AI-analyzed with safety scores and PubMed citations.
Standard of Care
Lecanemab (Leqembi), Donanemab — anti-amyloid antibodies. Cholinesterase inhibitors (donepezil, rivastigmine) for symptom management.
Prevalence
~6.9 million Americans aged 65+ living with Alzheimer's. Most common cause of dementia.
Research by Therapy Category
- Stem Cell Therapy Research
- Anktiva Immunotherapy Research
- Bioactive Peptide Research
- Gene Therapy & CRISPR Research
- Nutraceutical & Vitamin Research
- Antiparasitic Drug Repurposing Research
- Lifestyle Intervention Research
- Engineered Cell Therapy Research
- Off-Label Drug Repurposing Research
- Microbiome & Mitochondrial Intervention Research
- Diagnostic Test & Biomarker Research
- Computational Chemistry & Molecular Analysis
- Hormonal & Women's Health Research
- Disease Mechanism Education for Patients